Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma

Background Trabectedin is a novel anticancer agent used to treat soft tissue sarcoma (STS). This phase I study of trabectedin was performed to determine the recommended dose for phase II studies in Japanese patients with STS. Methods Patients who had STS refractory to, or who could not tolerate, ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Takafumi, Kakunaga, Shigeki, Ando, Masashi, Yonemori, Kan, Sugiura, Hideshi, Yamada, Kenji, Kawai, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101250/
https://www.ncbi.nlm.nih.gov/pubmed/24696229
http://dx.doi.org/10.1007/s10637-014-0094-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101250/
https://www.ncbi.nlm.nih.gov/pubmed/24696229
http://dx.doi.org/10.1007/s10637-014-0094-5

Ejemplares similares